Repetitive Blood Brain Barrier Opening for Alzheimer's Disease.
NCT ID: NCT06158789
Last Updated: 2023-12-06
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
NA
6 participants
INTERVENTIONAL
2022-06-02
2024-01-19
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Focused ultrasound treatment group
MR guided low intensity focused ultrasound
Low intensity focused ultrasound opens the blood brain barrier
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
MR guided low intensity focused ultrasound
Low intensity focused ultrasound opens the blood brain barrier
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* MMSE below 23
* FBB-PET positive
* FDG-PET shows alzheimer -induced neurodegeneration
* Dementia or cognitive impairment due to alzhemer's disease
* participants who have taken over 3 months of medication related with cognitive improvement
* Someone who can express their sensations during the procedure.
* Individuals who have voluntarily decided to participate in this clinical trial and have provided written consent on the informed consent form.
* Individuals with a commitment to adhere to the clinical trial protocol.
Exclusion Criteria
Note: Since the CGA-NPI requires the patient's caregiver to complete the survey, the caregiver must be present during the questionnaire.
Individuals with sensitivity/allergy or contraindications to the MRI contrast agents Gadolinium (Gadovist®) or ultrasound contrast agent Definity.
Contraindications:
Gadolinium (Gadovist®): Patients with untreated hypokalemia. Definity: Patients who have undergone right-left shunt, bidirectional shunt, or temporary right-left shunt, patients scheduled to undergo extracorporeal shock wave lithotripsy within 24 hours, clinically unstable or worsening congestive heart failure patients, acute myocardial infarction or acute coronary syndrome patients, patients at high risk of arrhythmias due to severe ventricular arrhythmias or prolongation of the QT interval, patients showing signs and symptoms of carbon dioxide retention or hypoxemia, patients with conditions that may induce pulmonary artery hypertension due to severe pulmonary insufficiency, severe pulmonary fibrosis, or damage to the pulmonary artery structure.
Individuals with standard contraindications to MR imaging, including the presence of metal devices incompatible with MRI.
Individuals with sensitivity/allergy or contraindications to anesthetic agents used for conscious sedation during procedures where conscious sedation is required.
Individuals with any of the following findings in the MRI examination:
Severe ischemic changes (Fazeka criteria score \> 2, Lacunes count \> 5, or Cerebral microbleeds count \> 3).
Active or chronic infection/inflammation. Acute or chronic bleeding. Tumor/space-occupying lesion. Meningeal enhancement. Intracranial hypotension.
Individuals with more than 30% of the skull area through which the sonication (Sonication) path passes covered with scars, scalp disorders (e.g., eczema), or atrophied scalp.
Individuals with a history of seizure disorder or epilepsy that could be exacerbated due to blood-brain barrier opening.
Individuals with a history of bleeding disorders.
Individuals with severe cardiac conditions or unstable hemodynamic status (e.g., uncontrollable hypertension, arrhythmias, angina, etc.).
Individuals with impaired kidney function (Glomerular filtration rate \< 30 mL/min/1.73 m²).
Individuals with severe brain atrophy to an extent that cannot be targeted.
Individuals who are HIV (Human Immunodeficiency Virus) positive and have a high likelihood of developing HIV encephalitis as HIV enters the brain parenchyma.
Individuals with potential vascular-origin infections that can enter the brain parenchyma, leading to meningitis or brain abscess.
Individuals with a thin blood-brain barrier, known to have homozygosity of the Apolipoprotein E allele (ApoE4).
Pregnant or lactating women.
For fertile women\*, those who have agreed to use clinically appropriate contraceptive methods\*\* during the trial period.
Definition of fertile women: Women who have experienced menarche and are not defined as postmenopausal after 12 months of amenorrhea without any surgical infertility procedures (e.g., hysterectomy or bilateral oophorectomy).
\*\* Clinically appropriate contraceptive methods: For women, it is defined as "\[Intrauterine device (e.g., loop, Mirena), chemical contraception (birth control pills), or subcutaneous contraceptive devices (e.g., Implanon)\] + Physical contraceptive methods (male or female)," and for tubal ligation or laparoscopic contraception (a type of tubal ligation).
Individuals currently participating in another clinical trial or who have participated in another clinical trial within 90 days of the screening date.
Other cases where the investigator deems participation in the clinical trial inappropriate due to ethical or potential impact on clinical trial results.
Specific reasons should be documented in the case record.
50 Years
85 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Yonsei University
OTHER
Kyung Won Chang
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Kyung Won Chang
Clinical professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jin Woo Chang, MD,PhD
Role: PRINCIPAL_INVESTIGATOR
Yonsei University
Byoung Seok Ye, MD,PhD
Role: STUDY_CHAIR
Yonsei University
Kyung Won Chang, MD
Role: STUDY_DIRECTOR
Yonsei University
Kyung Won Chang, MD,PhD
Role: STUDY_DIRECTOR
Yonsei University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Yonsei University Severance Hospital
Seoul, , South Korea
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Park SH, Baik K, Jeon S, Chang WS, Ye BS, Chang JW. Extensive frontal focused ultrasound mediated blood-brain barrier opening for the treatment of Alzheimer's disease: a proof-of-concept study. Transl Neurodegener. 2021 Nov 5;10(1):44. doi: 10.1186/s40035-021-00269-8.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
YUSHAD-02
Identifier Type: -
Identifier Source: org_study_id